NEKTAR THERAPEUTICS（NKTR）内部人交易：高管与董事近期交易
过去 18 个月，共有 8 位内部人为 NEKTAR THERAPEUTICS（NKTR）报告了 49 笔 Form 4 交易（最近一笔 2026-09-25）。
| 日期 | 内部人 | 职务 | 类型 | 股数 | 市值 |
|---|---|---|---|---|---|
| 2026-09-25 | GREER R SCOTT | 董事 | 买入 | 2,000 | $0 |
| 2026-09-25 | CHESS ROBERT | 董事 | 买入 | 2,000 | $0 |
| 2026-09-25 | Ajer Jeffrey Robert | 董事 | 买入 | 2,000 | $0 |
| 2026-09-25 | Brainard Diana | 董事 | 买入 | 2,000 | $0 |
| 2026-09-25 | WHITFIELD ROY A | 董事 | 买入 | 2,000 | $0 |
| 2026-08-20 | ROBIN HOWARD W | President & CEO | 卖出 | 418 | $30,088 |
| 2026-08-20 | Zalevsky Jonathan | Chief R&D Officer | 卖出 | 186 | $13,388 |
| 2026-07-02 | Zalevsky Jonathan | Chief R&D Officer | 卖出 | 5,681 | $397,670 |
| 2026-06-18 | ROBIN HOWARD W | President & CEO | 卖出 | 5,303 | $318,021 |
| 2026-06-18 | ROBIN HOWARD W | President & CEO | 卖出 | 4,697 | $285,155 |
| 2026-06-18 | ROBIN HOWARD W | President & CEO | 卖出 | 5,500 | $334,455 |
| 2026-06-18 | ROBIN HOWARD W | President & CEO | 卖出 | 4,500 | $277,425 |
| 2026-06-17 | Zalevsky Jonathan | Chief R&D Officer | 卖出 | 5,538 | $336,212 |
| 2026-05-21 | Zalevsky Jonathan | Chief R&D Officer | 卖出 | 199 | $13,036 |
| 2026-05-21 | ROBIN HOWARD W | President & CEO | 卖出 | 444 | $29,086 |
| 2026-02-20 | Zalevsky Jonathan | Chief R&D Officer | 卖出 | 180 | $13,140 |
| 2026-02-20 | ROBIN HOWARD W | President & CEO | 卖出 | 423 | $30,879 |
| 2026-01-22 | Zalevsky Jonathan | Chief R&D Officer | 卖出 | 3,867 | $137,936 |
| 2025-12-23 | ROBIN HOWARD W | President & CEO | 买入 | 21,667 | $0 |
| 2025-12-23 | Zalevsky Jonathan | Chief R&D Officer | 买入 | 6,250 | $0 |
| 2025-11-25 | Wilson Mark Andrew | Chief Legal Officer | 买入 | 1,903 | $0 |
| 2025-11-25 | Wilson Mark Andrew | Chief Legal Officer | 卖出 | 630 | $34,196 |
| 2025-11-25 | ROBIN HOWARD W | President & CEO | 买入 | 7,110 | $0 |
| 2025-11-25 | ROBIN HOWARD W | President & CEO | 卖出 | 2,207 | $119,796 |
| 2025-11-25 | Zalevsky Jonathan | Chief R&D Officer | 买入 | 2,666 | $0 |
来源：SEC Form 4 申报文件 · 截至 2026-09-25